Speakers
Professor Jon Coles
Stream 2
Outline of proposed content:
This session will describe the physiological concepts and clinical experience that underpin the use of targeted temperature control and blood transfusion to an optimal haemoglobin threshold in the management of critically ill patients with neurological disease. This includes patients admitted to the intensive care unit for neuroprotective therapy following cardiac arrest, ischaemic and haemorrhagic stroke, and traumatic brain injury. The session will consider the evidence from recent published trials and consensus guidelines on this topic and provide conclusions concerning current best practice. This session is being held in collaboration with the Neuroanaesthesia and Critical Care Society (NACCS), UK.
Learning objectives
1) Principles and application of targeted temperature control for neuroprotection in patients with brain injury
2) Impact of anaemia and blood transfusion on patient outcome in the ICU
3) How does the available evidence inform best practice in critically ill patients
Chair: Jon Coles joined by
Andrea Lavinio - Targeted temperature control for neuroprotection (20 mins)
Elisa Bogossian - Role of anaemia and blood transfusion in critically ill patient (20 mins)
Simon Stanworth - Optimal transfusion threshold in critically ill patient (20 mins)
I completed my clinical and academic training in Anaesthesia & Intensive Care Medicine in the Eastern region and was appointed as an Academic Consultant working within the Neurosciences and Trauma Critical Care Unit (NCCU) at Cambridge University Hospitals in 2006. My PhD was in the field of neuro-imaging (MR and Positron Emission Tomography (PET)) following traumatic brain injury (TBI). I was awarded a Clinician Scientist fellowship from the Academy of Medical Sciences/Health Foundation in 2004 and have maintained a research program funded by the Wellcome Trust, Medical Research Council (UK), European Union, and National Institute of Academic Anaesthesia that examines mechanisms responsible for secondary neuronal injury, their temporal profile, and implications for eventual neurocognitive recovery following TBI. I have published extensively within the field of neurosciences & critical care and am a reviewer for relevant specialist medical journals and national/international grant awarding bodies. In 2022 I was appointed as Clinical Professor of Intensive Care Medicine, University of Cambridge, UK and am currently President Elect, Neuroanaesthesia and Critical Care Society (NACCS), UK
Simon Stanworth is Consultant Haematologist at the John Radcliffe Hospital in Oxford (NHSBT and Oxford University Hospitals Foundation Trust), and Professor of Haematology and Transfusion Medicine, University of Oxford. He has over 20 years of clinical research experience since gaining his DPhil from the University of Oxford in ‘haemoglobin switching’. His research is informed by patient needs, identified by multiple Patient and Public Engagement panels and work with James Lind Priority Setting Partnerships. The main aim of his research is to understand which patients need (or don’t need) blood or alternatives to blood transfusion. His research is centred on clinical indications of blood transfusion components or alternatives to transfusion. Highlights have included international randomised trials. He has an interest in translating research into practice, including contributions to many national and international guidelines, such as red cell transfusion thresholds.
He is Director of the NIHR Blood Transfusion Research Unit (BTRU) Data Enabled Transfusion Practice which promises new data and new methods of assessing and improving transfusion practice. He has national and international leadership roles in transfusion medicine including Chair of the (formerly) National Cancer Research Institute Supportive Care Working Party, the European Haematology Association Transfusion Specialist Working Party, Chair of the International Collaboration for Transfusion Medicine Guidelines and co-Chair for the Biomedical Excellence for Safer Transfusion Collaborative (BEST)